Home Business Coronavirus outbreak: GAPL eyes, a drug manufacturer based on goa, are authorised to produce hydroxychloroquine sulfate

Coronavirus outbreak: GAPL eyes, a drug manufacturer based on goa, are authorised to produce hydroxychloroquine sulfate

by the owl speaks

Panaji: Goa Antibiotics Private Ltd (GAPL), a central public sector firm, has begun the process of obtaining a license to manufacture hydroxychloroquine sulfate that has been approved for COVID-19 by the Food and Drug Administration (FDA).
Under the administrative supervision of the Union Ministry of Health and Family Welfare, GAPL is a subsidiary of HLL Lifecare Limited.
The company has a production plant in Tuem, North Goa.
“The company has a license to manufacture chloroquine sulfate (not hydroxychloroquine sulfate), however, we have not manufactured it for the past 15 years.
However, we have now decided to obtain a license for hydroxychloroquine sulfate given the current demand,” said GAPL CEO Reju Skaria on Friday.
He said the company manufactured various pharmaceutical products according to demand.
“We have the potential to manufacture two crore tablets a month. We will
use this ability to produce any pharmaceutical product we are approved for,” he said.
Skaria stated that due to the current lockdown, there are difficulties in the
availability and transport of the Active Pharmaceutical Ingredient (API) needed for the formations.

You may also like

Leave a Comment

so